The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
RalGDS is required for tumor formation in a model of skin carcinogenesis
Open accessAbstract
To investigate the role of signaling by the small GTPase Ral, we have generated mice deficient for RalGDS, a guanine nucleotide exchange factor that activates Ral. We show that RalGDS is dispensable for mouse development but plays a substantial role in Ras-induced oncogenesis. Lack of RalGDS results in reduced tumor incidence, size, and progression to malignancy in multistage skin carcinogenesis, and reduced transformation by Ras in tissue culture. RalGDS does not appear to participate in the regulation of cell proliferation, but instead controls survival of transformed cells. Experiments performed in cells isolated from skin tumors suggest that RalGDS mediates cell survival through the activation of the JNK/SAPK pathway. These studies identify RalGDS as a key component in Ras-dependent carcinogenesis in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 2×
“While there is a large body of evidence supporting a key role for Raf/MAPK pathway in oncogenic Ras signaling, for example the restriction of Ras and BRAF mutations to the same tumor types and the mutual exclusivity of Ras and BRAF mutations (Davies et al. 2002), questions have been raised about the significance of Ra…”
BackgroundMethodSelf-citationSP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558 · cited 1×
“To determine whether JNK activation is responsible for the increased survival in RalGDS reconstituted cells, we blocked JNK activation with SP600125, a reversible JNK inhibitor (Bennett et al., 2001).”
BackgroundMice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., Turner, L., Rollins, B., Pasparakis, M., et al. (1999) · Nature Medicine · doi:10.1038/10552 · Cited by 839
Self-citationTuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
The exocyst is a Ral effector complex
Moskalenko, S., Henry, D. O., Rosse, C., Mirey, G., Camonis, J. H., & White, M. A. (2002) · Nature Cell Biology · doi:10.1038/ncb728 · Cited by 423 · cited 4×
“In a number of other tumor sys-targets in cancer, because their inhibition might be less toxic tems, JNK/SAPK signaling has been shown to provide a sur-than the inhibition of Raf signaling. vival signal (Hess et al., 2002), and of particular interest in this The data we present here suggests that RalGDS is an impor-co…”
BackgroundInfluentialSmall G protein Ral and its downstream molecules regulate endocytosis of EGF and insulin receptors
Nakashima, S., Morinaka, K., Koyama, S., Ikeda, M., Kishida, M., Okawa, K., Iwamatsu, A., Kishida, S., & Kikuchi, A. (1999) · The EMBO Journal · doi:10.1093/emboj/18.13.3629 · Cited by 231
The Brain Exocyst Complex Interacts with RalA in a GTP-dependent Manner
Brymora, A., Valova, V. A., Larsen, M. R., Roufogalis, B. D., & Robinson, P. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100320200 · Cited by 143 · cited 1×
“Therefore, if this protein is expressed GTP-bound Ral interacts with Sec5 (Brymora et al., 2001; in the RalGDS −/− mice, it would not respond to Ras-mediated Moskalenko et al., 2002), a component of the exocyst complex signaling.”
BackgroundRas-independent activation of Ral by a Ca2+-dependent pathway
Hofer, F., Berdeaux, R., & Steven Martin, G. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70327-6 · Cited by 80
Cited by
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
“Knockout mice have limited defects but show greatly reduced tumorigenicity in a skin-tumor model (Gonzalez-Garcia et al., 2005).”
BackgroundHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Metadata
- Authors
- González-García, A., Pritchard, C. A., Paterson, H. F., Mavria, G., Stamp, G., & Marshall, C. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 7
- Issue
- 3
- Pages
- 219-226
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1988911160
- Cited by
- 181
- References
- 8
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.